Preventive Asthma Drug Market Outlook 2020
Asthma is showing high prevalence worldwide. About 300 Million people are suffering from asthma. This is due to continuously deteriorating air quality, which is causing several allergies. In recent years, researchers have explored wide variety of preventive drugs that can delay asthma attacks. These drugs are being highly acknowledged by the doctors and consumers. The practice of prescribing preventive drugs by doctors is gaining momentum in the US, Europe and Asia-Pacific. Foreseeing the demand, several pharma players are shifting their R&D focus towards preventive asthma drugs. Some of the leading players in the pharma industry include Glaxosmithkline, Astrazeneca, Merck, Novartis, Roche, and others. The drugs by these players contributed millions of dollars to their revenue in 2014.
In its latest research, “Preventive Asthma Drug Market Outlook 2020”, RNCOS presents a comprehensive analysis of the industry. The report covers key drivers & challenges, and trends & developments that are peculiar to the drug market. The research includes estimated market figures of 2014, and forecasted numbers till 2020. The market was estimated at US$ 22 Billion in 2014. Our analysts have segmented the preventive asthma drug industry depending on the type of drugs and geographical distribution. A separate section is allotted to the competitive landscape, including the business overview of the key players and their SWOT analysis.
Our research revealed that inhaled corticosteroids were the most popular category of preventers during 2014. Researchers are combining corticosteroids with other form of drugs, such as long acting beta agonists in a single inhaler. The so called “combination therapy” is providing several benefits over the single dose. However, the market is facing few challenges like side-effects posed by such drugs, their high cost and lack of awareness in India, China, and other Middle East & Asia-Pacific countries.
Towards the end, RNCOS has suggested some recommendations to boost the preventers market in the coming future. On the whole, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the preventive asthma drugs industry.
In its latest research, “Preventive Asthma Drug Market Outlook 2020”, RNCOS presents a comprehensive analysis of the industry. The report covers key drivers & challenges, and trends & developments that are peculiar to the drug market. The research includes estimated market figures of 2014, and forecasted numbers till 2020. The market was estimated at US$ 22 Billion in 2014. Our analysts have segmented the preventive asthma drug industry depending on the type of drugs and geographical distribution. A separate section is allotted to the competitive landscape, including the business overview of the key players and their SWOT analysis.
Our research revealed that inhaled corticosteroids were the most popular category of preventers during 2014. Researchers are combining corticosteroids with other form of drugs, such as long acting beta agonists in a single inhaler. The so called “combination therapy” is providing several benefits over the single dose. However, the market is facing few challenges like side-effects posed by such drugs, their high cost and lack of awareness in India, China, and other Middle East & Asia-Pacific countries.
Towards the end, RNCOS has suggested some recommendations to boost the preventers market in the coming future. On the whole, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the preventive asthma drugs industry.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. ASTHMA - AN INTRODUCTION
4. DRIVERS & CHALLENGES
4.1 Drivers
4.1.1 Rising Healthcare Expenditure
4.1.2 Growing Geriatric Population
4.1.3 Increasing Prevalence of Asthma
4.1.4 Increasing R&D Driving Innovation
4.2 Challenges
4.2.1 High Cost of Drugs
4.2.2 Side Effects Caused By Drugs
4.2.3 Limited Demand from Developing Markets
4.2.4 Inadequate Awareness
5. PREVENTIVE ASTHMA DRUGS MARKET OVERVIEW
6. MARKET SEGMENTATION
6.1 By Type of Drugs
6.2 By Geography
7. TRENDS & DEVELOPMENTS
7.1 Combined Therapy Benefitting Asthma Patients
7.2 Monoclonal Antibody: An Emerging Effective Treatment for Asthma
7.3 Asthma Tracking Tool Aiding Disease Management
8. COMPETITIVE ASSESSMENT
8.1 Market Share of Key Players
8.2 Top Selling Preventive Asthma Drugs
8.3 Profiles
8.3.1 Glaxosmithkline
8.3.2 Astrazeneca
8.3.3 Merck
8.3.4 Roche
8.3.5 Novartis
9. RECOMMENDATIONS
2. RESEARCH METHODOLOGY
3. ASTHMA - AN INTRODUCTION
4. DRIVERS & CHALLENGES
4.1 Drivers
4.1.1 Rising Healthcare Expenditure
4.1.2 Growing Geriatric Population
4.1.3 Increasing Prevalence of Asthma
4.1.4 Increasing R&D Driving Innovation
4.2 Challenges
4.2.1 High Cost of Drugs
4.2.2 Side Effects Caused By Drugs
4.2.3 Limited Demand from Developing Markets
4.2.4 Inadequate Awareness
5. PREVENTIVE ASTHMA DRUGS MARKET OVERVIEW
6. MARKET SEGMENTATION
6.1 By Type of Drugs
6.2 By Geography
7. TRENDS & DEVELOPMENTS
7.1 Combined Therapy Benefitting Asthma Patients
7.2 Monoclonal Antibody: An Emerging Effective Treatment for Asthma
7.3 Asthma Tracking Tool Aiding Disease Management
8. COMPETITIVE ASSESSMENT
8.1 Market Share of Key Players
8.2 Top Selling Preventive Asthma Drugs
8.3 Profiles
8.3.1 Glaxosmithkline
8.3.2 Astrazeneca
8.3.3 Merck
8.3.4 Roche
8.3.5 Novartis
9. RECOMMENDATIONS
LIST OF FIGURES:
Figure 3-1: Diagnostic Flow - Chart for Asthma in Clinical Practices
Figure 5-1: Global - Preventive Asthma Drugs Market (Billion US$), 2014-2020
Figure 6-1: Global - Preventive Asthma Drugs Market by Different Types of Drugs (%), 2014
Figure 6-2: Global - Preventive Asthma Drugs Market by Geography (%), 2014
Figure 8-1: Share of Major Players in Preventive Asthma Drugs Market (%), 2014
Figure 8-2: Glaxosmithkline Plc - Revenue by Geographical Regions (%), 2014
Figure 8-3: Astrazeneca - Revenue by Geographical Regions (%), 2014
Figure 8-4: Merck - Revenue by Geographical Regions (%), 2014
Figure 8-5: Roche - Revenue by Geographical Regions (%), 2014
Figure 8-6: Novartis - Revenue by Geographical Regions (%), 2014
Figure 3-1: Diagnostic Flow - Chart for Asthma in Clinical Practices
Figure 5-1: Global - Preventive Asthma Drugs Market (Billion US$), 2014-2020
Figure 6-1: Global - Preventive Asthma Drugs Market by Different Types of Drugs (%), 2014
Figure 6-2: Global - Preventive Asthma Drugs Market by Geography (%), 2014
Figure 8-1: Share of Major Players in Preventive Asthma Drugs Market (%), 2014
Figure 8-2: Glaxosmithkline Plc - Revenue by Geographical Regions (%), 2014
Figure 8-3: Astrazeneca - Revenue by Geographical Regions (%), 2014
Figure 8-4: Merck - Revenue by Geographical Regions (%), 2014
Figure 8-5: Roche - Revenue by Geographical Regions (%), 2014
Figure 8-6: Novartis - Revenue by Geographical Regions (%), 2014
LIST OF TABLES:
Table 8-1: Revenues of Top Selling Preventive Asthma Drugs (Million US$), 2014
Table 8-2: Glaxosmithkline Plc - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 8-3: Astrazeneca - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 8-4: Merck - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 8-5: Roche: Revenue by Business Segments (Billion US$), 2013 & 2014
Table 8-6: Novartis - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 8-1: Revenues of Top Selling Preventive Asthma Drugs (Million US$), 2014
Table 8-2: Glaxosmithkline Plc - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 8-3: Astrazeneca - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 8-4: Merck - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 8-5: Roche: Revenue by Business Segments (Billion US$), 2013 & 2014
Table 8-6: Novartis - Revenue by Business Segments (Billion US$), 2013 & 2014
